Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools

被引:36
|
作者
Lynch, DR
Farmer, JM
Wilson, RL
Balcer, LJ
机构
[1] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
composite measure; mitochondrial disease; antioxidant; cardiomyopathy; diabetes;
D O I
10.1002/mds.20449
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although several neuroprotective agents have been proposed as potential therapies in Friedreich ataxia (FA), clinical trials of their efficacy are limited by a lack of sensitive outcome measures. We assessed whether performance measures (nine-hole peg test, the timed 25-foot walk, and low-contrast letter acuity) provide valid measures of disease status in FA. Scores for each measure correlated significantly with neurologic disability and disease duration. Rank correlations between scores for performance measures were moderate in magnitude, Suggesting that the each test captures separate yet related dimensions of neurological function in FA. Linear regression models demonstrated that scores from the nine-hole peg test and the timed 25-foot walk (after reciprocal transformation) were predicted by age and triplet repeat length in patients with FA. In addition, comparison of the temporal courses of change for each performance measure demonstrated that scores from the timed 25-foot walk change early in the Course of FA, nine-hole peg test scores change slowly over the full course of the disorder, and low-contrast letter acuity scores change in the later stages of the disease. Thus, a composite scale derived from these performance measures may provide the best overall measure for assessing disease progression throughout the illness. (c) 2005 Movement Disorder Society.
引用
收藏
页码:777 / 782
页数:6
相关论文
共 41 条
  • [21] Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia
    Nabhan, Joseph F.
    Wood, Kristy M.
    Rao, Varada P.
    Morin, Jeffrey
    Bhamidipaty, Surya
    LaBranche, Timothy P.
    Gooch, Renea L.
    Bozal, Fazli
    Bulawa, Christine E.
    Guild, Braydon C.
    SCIENTIFIC REPORTS, 2016, 6
  • [22] The potential of the novel NAD+ supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich's ataxia
    Chiang, Shannon
    Kalinowski, Danuta S.
    Dharmasivam, Mahendiran
    Braidy, Nady
    Richardson, Des R.
    Huang, Michael L. H.
    PHARMACOLOGICAL RESEARCH, 2020, 155
  • [23] Friedreich ataxia presenting as sudden cardiac death in childhood: Clinical, genetic and pathological correlation, with implications for genetic testing and counselling
    Quercia, Nada
    Somers, Gino R.
    Halliday, William
    Kantor, Paul F.
    Banwell, Brenda
    Yoon, Grace
    NEUROMUSCULAR DISORDERS, 2010, 20 (05) : 340 - 342
  • [24] Potential biomarker identification for Friedreich's ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion
    McMackin, Marissa Z.
    Durbin-Johnson, Blythe
    Napierala, Marek
    Napierala, Jill S.
    Ruiz, Luis
    Napoli, Eleonora
    Perlman, Susan
    Giulivi, Cecilia
    Cortopassi, Gino A.
    PLOS ONE, 2019, 14 (10):
  • [25] Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia
    Martelli, Alain
    Friedman, Lisa S.
    Reutenauer, Laurence
    Messaddeq, Nadia
    Perlman, Susan L.
    Lynch, David R.
    Fedosov, Kathrin
    Schulz, Joerg B.
    Pandolfo, Massimo
    Puccio, Helene
    DISEASE MODELS & MECHANISMS, 2012, 5 (06) : 860 - 869
  • [26] Feasible and clinical relevant outcome measures for adults with mitochondrial disease
    Bergs, Peggy M. J.
    Maas, Daphne M.
    Janssen, Mirian C. H.
    Groothuis, Jan T.
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (01) : 102 - 108
  • [27] E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia
    Benini, Monica
    Fortuni, Silvia
    Condo, Ivano
    Alfedi, Giulia
    Malisan, Florence
    Toschi, Nicola
    Serio, Dario
    Massaro, Damiano Sergio
    Arcuri, Gaetano
    Testi, Roberto
    Rufini, Alessandra
    CELL REPORTS, 2017, 18 (08): : 2007 - 2017
  • [28] The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients
    Pane, Chiara
    Trinchillo, Assunta
    Salzano, Andrea
    Marsili, Angela
    Puorro, Giorgia
    Cittadini, Antonio
    Sacca, Francesco
    Russo, Cinzia Valeria
    CEREBELLUM, 2023, 22 (05) : 1034 - 1038
  • [29] Apparent Opportunities and Hidden Pitfalls: The Conflicting Results of Restoring NRF2-Regulated Redox Metabolism in Friedreich's Ataxia Pre-Clinical Models and Clinical Trials
    Tiberi, Jessica
    Segatto, Marco
    Fiorenza, Maria Teresa
    La Rosa, Piergiorgio
    BIOMEDICINES, 2023, 11 (05)
  • [30] The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients
    Chiara Pane
    Assunta Trinchillo
    Andrea Salzano
    Angela Marsili
    Giorgia Puorro
    Antonio Cittadini
    Francesco Saccà
    Cinzia Valeria Russo
    The Cerebellum, 2023, 22 : 1034 - 1038